Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental drugs
CGS-20625
Другие языки:

    CGS-20625

    Подписчиков: 0, рейтинг: 0
    CGS-20625
    CGS-20625.svg
    Clinical data
    Routes of
    administration    		 By mouth
    ATC code
    • none
    Pharmacokinetic data
    Bioavailability 41%
    Identifiers
    • 5,6,7,8,9,10-hexahydro-2-(4-methoxyphenyl)-cyclohepta[b]pyrazolo[3,4-d]pyridin-3(2H)-one
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    CompTox Dashboard (EPA)
    Chemical and physical data
    Formula C18H19N3O2
    Molar mass 309.369 g·mol−1
    3D model (JSmol)
    • COC1=CC=C(C=C1)N2C(=O)C3=CN=C4CCCCCC4=C3N2
    • InChI=1S/C18H19N3O2/c1-23-13-9-7-12(8-10-13)21-18(22)15-11-19-16-6-4-2-3-5-14(16)17(15)20-21/h7-11,20H,2-6H2,1H3 ☒N
    • Key:UBLXQFIFWUEVGJ-UHFFFAOYSA-N ☒N
     ☒NcheckY (what is this?)  (verify)

    CGS-20625 is an anxiolytic drug used in scientific research. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. It produces anxiolytic and anticonvulsant effects, but with no sedative effects even at high doses, and no significant muscle relaxant effects. It is orally active in humans, but with relatively low bioavailability.

    CGS-20625 is a positive allosteric modulator at several GABAA receptors types. Due to its alicyclic moiety potency at γ1 subunit, containing receptor types is more pronounced for CGS-20625 compared to benzodiazepines. γ1 subunits are expressed at higher levels in the central amygdala.



    Новое сообщение